Navigation Links
RNA Aptamers: A New Paradigm in Cancer Diagnosis and Treatment, New Life Science Webinar Hosted by Xtalks
Date:10/30/2013

Toronto, Canada (PRWEB) October 30, 2013

RNA aptamers are an emerging class of molecules demonstrating significant potential in the diagnosis and treatment of human diseases. RNA aptamers are small, single-stranded RNA molecules that are functionally analogous to antibodies. However, RNA aptamers can be produced by chemical synthesis and their small size, low immunogenicity, and other attributes give them important advantages over antibodies. In addition, stable, ribonuclease-resistant RNA aptamers can be readily produced which further extends their use for both in vitro and in vivo applications.

This presentation will focus on the use of RNA aptamers for developing cancer diagnostics and treatments.

Join the panel including speakers from University of Miami, University of Arlington, TX, and University of Iowa, as they discuss techniques and methods involved in:

  •     Selecting and using RNA aptamers as therapeutic agents
  •     Targeted delivery of therapeutics such as siRNA
  •     Development of biosensors/diagnostics for early cancer detection

A Q&A with the audience will follow the main presentation.

For more information about this event or to register, visit: http://xtalks.com/rna-aptamers-in-cancer-diagnosis-and-treatment.ashx .

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Michelle Tran, Marketing Manager
+1 (416) 977-6555 ext 284
mtran(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/10/prweb11269970.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. INCOM Inc. Announces Acquisition of Paradigm Optics
2. Unique properties of graphene lead to a new paradigm for low-power telecommunications
3. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
4. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
5. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
6. Study Published in Nature Biotechnology Demonstrates Ability of Modernas Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
7. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
8. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
9. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
10. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
11. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 18, 2017 , ... Opal Kelly, a leading producer of ... announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 interface ... factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface delivers ...
(Date:1/18/2017)... 18, 2017   Boston Biomedical , an industry ... target cancer stemness pathways, will feature data from two ... the 2017 ASCO Gastrointestinal Cancers Symposium, held from January ... Napabucasin is an orally-administered investigational agent designed ... Cancer stem cells (CSCs) possess the property of ...
(Date:1/18/2017)...   Parent Project Muscular Dystrophy (PPMD) , a ... muscular dystrophy (Duchenne) , today announced a $600,000 grant ... Technology (NJIT) and Talem Technologies (Talem) as part of ... to assist people living with Duchenne. PPMD is funding ... embedded computer, software, a force sensor and a motor ...
(Date:1/18/2017)... ... 18, 2017 , ... Total Orthopedics and Sports Medicine ( ... The operation took place on Wednesday, January 11, 2017 at Long Island Jewish, ... cervical discectomy and fusion on a 42 year old female who was in ...
Breaking Biology Technology:
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
(Date:1/3/2017)... -- Onitor, provider of digital health technology for consumers, ... biometric data-driven program designed to aid weight loss for ... Consumer Electronics Show (CES) in Las Vegas ... World Health Organization (WHO), have identified lifestyle risks that ... overweight or obese. WHO also states that more people ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
Breaking Biology News(10 mins):